

PRESS RELEASE


Braunschweig, [date] 2020

Together with Prof. Cicin-Sain and Dr. Rand from the Helmholtz Centre for Infection Research, InSCREENeX wins BMBF support for COVID-19/SARS-CoV-2 research

Together with Prof. Cicin-Sain and Dr. Ulfert Rand from the Helmholtz Centre for Infection Research, InSCREENeX GmbH has secured funding under the Rapid Response Module of the *Richtlinie zur Förderung eines Nationalen Forschungsnetzes zoonotische Infektionskrankheiten*.

The project: HULK-CoV2

→ **HU**man Lung model for **Key** screens and preclinical validation of antivirals against SARS-**CoV-2** infection.



With the emergence of SARS-CoV-2 understanding mechanisms of infection and rapid screens of potential antivirals are urgently needed. Currently used in vitro models either do not reflect the physiologically relevant environment of SARS-CoV-2 infection (for example Vero, Caco-2, Calu-3 cells), or, in the case of primary airway cells, do not lend themselves for high-throughput assays.

We therefore combine our expertise in generating physiologically relevant cell lines with the virological expertise of Prof. Cicin-Sain and Dr. Rand from the Helmholtz Centre for Infection Research to generate in vitro models of human SARS-CoV-2 airway infection.

These models will be genetically engineered to work in image-based high throughput assay studying mechanism of infection, identifying antiviral targets and screening for antiviral compounds.

GEFÖRDERT VOM



Bundesministerium
für Bildung
und Forschung

This project has received funding from the Bundesministerium für Bildung und Forschung; programme: Rapid Response Modul der Förderbekanntmachung „Richtlinie zur Förderung eines Nationalen Forschungsnetzes zoonotische Infektionskrankheiten“ under grant agreement No 01KI20140.

Contact InSCREENeX GmbH

Tom Wahlicht
Business Development
tom.wahlicht@inscreenex.com

InSCREENeX GmbH
Inhoffenstr. 7
38124 Braunschweig, Germany
www.inscreenex.com

About InSCREENeX GmbH

InSCREENeX establishes novel mammalian cell systems that support the drug development process. InSCREENeX's product solutions speed up drug development (SCREENflex) and enable physiologically relevant tests in vitro under in vivo conditions (CI-SCREEN).

SCREENflex aims at earlier stages of the drug development process as it allows to establish stable recombinant cells which overexpress e.g. drug targets like GPCRs, ion channels or kinases. These customized cell lines are robust and thus are used by the customers in high-throughput screenings to identify lead candidates. The main advantages of SCREENflex are the rapid turnaround time (4-6 weeks) and the possibility to adjust the extent of target expression to a desired level.

CI-SCREEN is a functional immortalization technology enabling the generation of novel cell systems from any primary cell. These cell systems are available in unlimited amounts, easy to use and, most importantly, reflect the physiology of cells found in the body. This enables the production of an infinite number of tissue-like cells for every application in drug development.